For the quarter ending 2025-09-30, PBYI made $54,475,000 in revenue. $8,844,000 in net income. Net profit margin of 16.23%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 54,475,000 | 52,436,000 | 46,007,000 | 51,421,500 |
| Cost of sales | 12,173,000 | 12,301,000 | 10,556,000 | 12,324,500 |
| Selling, general and administrative | 16,817,000 | 18,047,000 | 17,604,000 | 19,186,000 |
| Research and development | 15,912,000 | 15,452,000 | 13,863,000 | 14,378,000 |
| Total operating costs and expenses | 44,902,000 | 45,800,000 | 42,023,000 | 45,888,500 |
| Income from operations | 9,573,000 | 6,636,000 | 3,984,000 | 5,533,000 |
| Interest income | 1,044,000 | 956,000 | 1,101,000 | 1,099,000 |
| Interest expense | 1,489,000 | 1,837,000 | 2,177,000 | 2,990,000 |
| Other income | 115,000 | 410,000 | 359,000 | 179,500 |
| Total other expenses, net | -330,000 | -471,000 | -717,000 | -1,711,500 |
| Net income before income taxes | 9,243,000 | 6,165,000 | 3,267,000 | 3,821,500 |
| Income tax expense | 399,000 | 310,000 | 293,000 | 224,250 |
| Deferred income tax benefit | - | - | - | 110,250 |
| Net income | 8,844,000 | 5,855,000 | 2,974,000 | 7,245,000 |
| Basic (in dollars per share) | 0.18 | 0.12 | 0.06 | 0.15 |
| Diluted (in dollars per share) | 0.17 | 0.12 | 0.06 | 0.15 |
| Weighted average common stock outstanding for basic net income per share (in shares) | 50,339,456 | 49,700,217 | 49,595,697 | -24,326,088.5 |
| Weighted-average shares of common stock outstandingdiluted (in shares) | 50,929,893 | 50,144,704 | 49,906,341 | -24,182,671 |
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)